Rontalizumab
Rontalizumab is a humanized IgG1 monoclonal antibody targets IFN-α. Rontalizumab can be used for the research of systemic lupus erythematosus[1].
Product Specifications
CAS Number
[948570-30-7]
Product Name Alternative
RhuMab IFNalpha; Anti-Human IFN alpha Recombinant Antibody
UNSPSC
12352203
Target
Others
Type
Inhibitory Antibodies
Related Pathways
Others
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/rontalizumab.html
Purity
99.08
Solubility
10 mM in DMSO
Smiles
[Rontalizumab]
Molecular Weight
(146.18 kDa)
References & Citations
[1]McBride JM, et al. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum. 2012 Nov;64 (11) :3666-76.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
040625-ML550 100 µL
PTGES3, ID (PTGES3, P23, TEBP, Prostaglandin E synthase 3, Cytosolic prostaglandin E2 synthase, Hsp90 co-chaperone, Progesterone receptor complex p23, Telomerase-binding protein p23) (MaxLight 550) discontinued
Ask
View Details 
